Models can be organized around disruptions in hepatocyte transporters, bile duct function, or regulatory pathways controlling bile acid synthesis, secretion, and clearance. Comparing these mechanisms helps determine how impaired handling produces accumulation of biliary substances and contributes to downstream liver injury. This framework connects a specific experimental disturbance with the biological processes involved in cholestatic disease.
Cellular, organoid, and animal systems provide complementary ways to investigate cholestatic injury. They can be used to examine altered bile handling, hepatotoxicity, inflammation, fibrosis, and liver repair across experimental settings. Including these model categories broadens the research question from a molecular or cellular mechanism to more complex patterns of tissue injury and recovery relevant to medicine.
These pathways represent distinct points at which bile acid balance can be disturbed. Altered synthesis may change the amount produced, while impaired secretion or clearance can promote retention and accumulation. Examining the pathways separately helps researchers associate a model's initiating defect with its effects on hepatotoxicity and other cholestatic injury processes.
Selection should follow the biological question being tested. A study focused on hepatocyte transporters or bile acid regulation may use a cellular or organoid system, whereas broader investigation of inflammation, fibrosis, or liver repair may require a model that captures more complex liver responses. Matching model scope to the intended outcome improves interpretability.
These models can support biomarker discovery by linking experimental cholestatic injury with measurable biological changes. They also allow investigation of hepatotoxicity, inflammation, fibrosis, and liver repair, creating several outcome categories rather than a single injury measurement. Such findings can help identify signals relevant to cholestatic disease and drug-induced liver injury research.
A cholestasis research model can be used to examine whether a drug-related disturbance affects biliary transport, bile duct function, or bile acid regulation. Researchers can then evaluate associated hepatotoxicity and related responses such as inflammation or fibrosis. This application supports assessment of drug-induced liver injury and can inform the development of therapies for cholestatic liver diseases.